Table 4.
Study and ref. | Genesa | Number of controls; number of cases | Outcome | Estimate of effect (OR and 95% CI) | P value | Unit of estimated effect |
---|---|---|---|---|---|---|
Mokry et al.96 | DHCR7, CYP2R1, GC and CYP24A1 | 38,589; 14,498 | Multiple sclerosis | 2.02 (1.65–2.46) | 7.7 × 10−12 | One standard deviation decrease in log-transformed 25OHD level |
Rhead et al.99 | DHCR7, CYP2R1 and GC | 22,168; 7,391 | Multiple sclerosis | 0.85 (0.76–0.94) | 0.003 | Unit change in polygenic risk score |
Jacobs et al.97 | CYP2R1, DHCR7, CYP24A1, SEC23A and AMDHD1 | 41,505; 14,802 | Multiple sclerosis | 0.57 (0.41–0.81) | 0.001 | One unit increase in natural log-transformed vitamin D level |
Gianfrancesco et al.98 | GC, CYP2R1 and DHCR7 | 1,715; 34 | Paediatric-onset multiple sclerosis | 0.72 (0.55–0.94) | 0.02 | NA |
25OHD, 25-hydroxyvitamin D; NA, not applicable. aGenes in which variants can be used to infer serum 25OHD concentration.